Schrödinger (NASDAQ:SDGR – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12), Zacks reports. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company had revenue of $35.30 million during the quarter, compared to analysts’ expectations of $41.25 million. During the same period in the prior year, the firm earned ($0.86) EPS. Schrödinger’s quarterly revenue was down 17.1% on a year-over-year basis. Schrödinger updated its FY 2024 guidance to EPS.
Schrödinger Trading Down 7.8 %
Shares of SDGR opened at $20.37 on Friday. Schrödinger has a 1-year low of $16.67 and a 1-year high of $38.00. The firm’s 50-day moving average price is $18.76 and its 200-day moving average price is $20.42. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -8.71 and a beta of 1.50.
Insider Buying and Selling
In other Schrödinger news, insider Margaret Dugan sold 1,531 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total value of $27,221.18. Following the completion of the transaction, the insider now owns 13,469 shares in the company, valued at approximately $239,478.82. This represents a 10.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.60% of the stock is owned by insiders.
Analyst Ratings Changes
Get Our Latest Stock Report on Schrödinger
Schrödinger Company Profile
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Featured Articles
- Five stocks we like better than Schrödinger
- What Does Downgrade Mean in Investing?
- Top-Performing Non-Leveraged ETFs This Year
- 3 Healthcare Dividend Stocks to Buy
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- The How and Why of Investing in Gold Stocks
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.